Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Accounts Payables: 2014-2025

Historic Accounts Payables for vTv Therapeutics (VTVT) over the last 11 years, with Sep 2025 value amounting to $9.8 million.

  • vTv Therapeutics' Accounts Payables rose 57.45% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 57.45%. This contributed to the annual value of $5.0 million for FY2024, which is 50.92% down from last year.
  • As of Q3 2025, vTv Therapeutics' Accounts Payables stood at $9.8 million, which was up 87.94% from $5.2 million recorded in Q2 2025.
  • vTv Therapeutics' Accounts Payables' 5-year high stood at $12.5 million during Q1 2022, with a 5-year trough of $4.2 million in Q1 2025.
  • Its 3-year average for Accounts Payables is $7.6 million, with a median of $8.4 million in 2023.
  • In the last 5 years, vTv Therapeutics' Accounts Payables skyrocketed by 151.24% in 2022 and then tumbled by 52.00% in 2025.
  • Over the past 5 years, vTv Therapeutics' Accounts Payables (Quarterly) stood at $8.0 million in 2021, then fell by 8.85% to $7.3 million in 2022, then soared by 40.05% to $10.2 million in 2023, then plummeted by 50.92% to $5.0 million in 2024, then soared by 57.45% to $9.8 million in 2025.
  • Its Accounts Payables was $9.8 million in Q3 2025, compared to $5.2 million in Q2 2025 and $4.2 million in Q1 2025.